Cargando…

Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy

The term ribosome-inactivating protein (RIP) is used to denominate proteins mostly of plant origin, which have N-glycosidase enzymatic activity leading to a complete destruction of the ribosomal function. The discovery of the RIPs was almost a century ago, but their usage has seen transition only in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilabert-Oriol, Roger, Weng, Alexander, von Mallinckrodt, Benedicta, Melzig, Matthias F, Fuchs, Hendrik, Thakur, Mayank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296666/ https://www.ncbi.nlm.nih.gov/pubmed/25341935 http://dx.doi.org/10.2174/1381612820666140826153913

Ejemplares similares

Reporter Assay for Endo/Lysosomal Escape of Toxin-Based Therapeutics
por: Gilabert-Oriol, Roger, et al.
Publicado: (2014)

Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers
por: Fuchs, Hendrik, et al.
Publicado: (2016)

An unusual type I ribosome-inactivating protein from Agrostemma githago L.
por: Weise, Christoph, et al.
Publicado: (2020)

Ribosome-Inactivating and Related Proteins
por: Schrot, Joachim, et al.
Publicado: (2015)

Use of Ribosome-Inactivating Proteins from Sambucus for the Construction of Immunotoxins and Conjugates for Cancer Therapy
por: Ferreras, José M., et al.
Publicado: (2011)

The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations
por: Rust, Aleksander, et al.
Publicado: (2017)

A novel recombinant immunotoxin with the smallest ribosome-inactivating protein Luffin P1: T-cell cytotoxicity and prolongation of allograft survival
por: Wang, Rupeng, et al.
Publicado: (2010)

Anti-Human Endoglin (hCD105) Immunotoxin—Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1
por: Barriuso, Begoña, et al.
Publicado: (2016)

Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.
por: Stirpe, F., et al.
Publicado: (1988)

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
por: Lv, Minghua, et al.
Publicado: (2015)

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861
por: Bhargava, Cheenu, et al.
Publicado: (2017)

Inactivation of Salmonella enterica on post-harvest cantaloupe and lettuce by a lytic bacteriophage cocktail
por: Wong, Catherine W.Y., et al.
Publicado: (2019)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Structures and Ribosomal Interaction of Ribosome-Inactivating Proteins
por: Shi, Wei-Wei, et al.
Publicado: (2016)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro
por: Deng, Cuimin, et al.
Publicado: (2017)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
por: Wang, Chunguang, et al.
Publicado: (2016)

Ribosome Inactivating Proteins from Rosaceae
por: Shang, Chenjing, et al.
Publicado: (2016)

Antiviral Activity of Ribosome-Inactivating Proteins
por: Citores, Lucía, et al.
Publicado: (2021)

Biological Activities of Ribosome-Inactivating Proteins
por: Citores, Lucía, et al.
Publicado: (2023)

Systemic immunotoxin therapy of cancer: advances and prospects.
por: Wawrzynczak, E. J.
Publicado: (1991)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Immunotoxins: A Review of Their Use in Cancer Treatment
por: Aruna, G
Publicado: (2006)

Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

Antibody-Based Immunotoxins for Colorectal Cancer Therapy
por: Sanz, Laura, et al.
Publicado: (2021)

Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain
Publicado: (1984)

Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A
por: Lee, Byeong Sung, et al.
Publicado: (2019)

Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24
por: Hedberg-Oldfors, Carola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_idu230iskbd7cihlq6lfscc0q9